Trials / Completed
CompletedNCT00778700
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
A Double-Blind, Randomized, Vehicle-Controlled Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participants in each.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo Cream | Cream with no active drug |
| DRUG | Ruxolitinib Phosphate | Ruxolitinib phosphate cream |
Timeline
- Start date
- 2008-10-28
- Primary completion
- 2009-06-26
- Completion
- 2009-06-26
- First posted
- 2008-10-23
- Last updated
- 2022-02-09
- Results posted
- 2022-02-09
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00778700. Inclusion in this directory is not an endorsement.